Rafferty Asset Management
AXSM icon

Rafferty Asset Management’s Axsome Therapeutics AXSM Stock Holding History

Rafferty Asset Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,567
Closed -$286K – 1069
2025
Q4 		$286K Sell
1,567
-175
-10% -$24.4K ﹤0.01% 1008
2025
Q3 		$212K Sell
1,742
-457
-21% -$51.5K ﹤0.01% 1064
2025
Q2 		$230K Sell
2,199
-530
-19% -$56.1K ﹤0.01% 1027
2025
Q1 		$318K Sell
2,729
-901
-25% -$103K ﹤0.01% 949
2024
Q4 		$307K Sell
3,630
-1,054
-23% -$96.9K ﹤0.01% 1021
2024
Q3 		$421K Sell
4,684
-793
-14% -$69.2K ﹤0.01% 981
2024
Q2 		$441K Sell
5,477
-1,385
-20% -$103K ﹤0.01% 962
2024
Q1 		$548K Buy
6,862
+1,025
+18% +$86K ﹤0.01% 950
2023
Q4 		$465K Buy
5,837
+1,277
+28% +$85.4K ﹤0.01% 998
2023
Q3 		$319K Buy
4,560
+205
+5% +$15.3K ﹤0.01% 1011
2023
Q2 		$313K Sell
4,355
-158
-4% -$11.7K ﹤0.01% 1036
2023
Q1 		$278K Buy
4,513
+556
+14% +$36.5K ﹤0.01% 1055
2022
Q4 		$305K Buy
+3,957
New +$237K ﹤0.01% 1013
2022
Q3 		– Sell
-9,734
Closed -$373K – 1154
2022
Q2 		$373K Buy
9,734
+4,243
+77% +$134K ﹤0.01% 850
2022
Q1 		$227K Sell
5,491
-10,851
-66% -$336K ﹤0.01% 1129
2021
Q4 		$617K Sell
16,342
-1,076
-6% -$39.6K ﹤0.01% 1021
2021
Q3 		$574K Buy
17,418
+13,825
+385% +$539K ﹤0.01% 1011
2021
Q2 		$242K Buy
+3,593
New +$216K ﹤0.01% 1207
2021
Q1 		– Sell
-3,984
Closed -$325K – 1161
2020
Q4 		$325K Sell
3,984
-85
-2% -$6.36K ﹤0.01% 792
2020
Q3 		$290K Sell
4,069
-66
-2% -$5.14K ﹤0.01% 824
2020
Q2 		$340K Buy
+4,135
New +$318K ﹤0.01% 801
2020
Q1 		– Sell
-4,545
Closed -$470K – 617
2019
Q4 		$470K Sell
4,545
-8,285
-65% -$335K 0.01% 698
2019
Q3 		$260K Buy
+12,830
New +$330K ﹤0.01% 759

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rafferty Asset Management's AXSM Position: Q1 2026 in Review

Rafferty Asset Management sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 1,567 shares — an estimated $286K sold.

Rafferty Asset Management first reported a position in AXSM in Q3 2019 and held it in 23 quarters. The position peaked at $617K in Q4 2021. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Rafferty Asset Management reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Rafferty Asset Management sold 1,567 Axsome Therapeutics shares in Q1 2026, an estimated $286K.
  • Rafferty Asset Management first reported a position in Axsome Therapeutics in Q3 2019 and held it in 23 quarters.
  • Rafferty Asset Management's Axsome Therapeutics position peaked at $617K in Q4 2021.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Rafferty Asset Management's 13F filing for Q1 2026, filed 15 May 2026.